Linagliptin reduces ischemic brain damage following stroke in a high-fat diet mouse model: A comparison to Glimepiride

Aims: Type 2 Diabetes (T2D) is a major risk factor for premature and severe stroke. Linagliptin is a dipeptidyl peptidase (DPP)-4 inhibitor with unique pharmacological properties approved for the treatment of T2D. The aim of this study was to determine the efficacy of linagliptin in protecting against stroke-induced ischemic brain damage in a diabetic animal model. Methods: C57BL/6J male mice fed a high-fat diet for 36 weeks were treated with oral linagliptin (10 mg/kg/d; n = 7), the sulfonylurea glimepiride (2.5 mg/kg/d; n = 7), or vehicle (n = 7) during Weeks 30 – 36. Blood glucose levels, body weight, and foo…